These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34921596)

  • 61. [Spinal muscular atrophy treated with nusinersen].
    Boesen MS; Albrechtsen S; Born AP
    Ugeskr Laeger; 2019 Jan; 181(2):. PubMed ID: 30618374
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study.
    Acsadi G; Crawford TO; Müller-Felber W; Shieh PB; Richardson R; Natarajan N; Castro D; Ramirez-Schrempp D; Gambino G; Sun P; Farwell W
    Muscle Nerve; 2021 May; 63(5):668-677. PubMed ID: 33501671
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience.
    Veerapandiyan A; Eichinger K; Guntrum D; Kwon J; Baker L; Collins E; Ciafaloni E
    Muscle Nerve; 2020 Feb; 61(2):222-226. PubMed ID: 31773738
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Effect of Nusinersen Therapy on Laboratory Parameters of Patients with Spinal Muscular Atrophy.
    Sarıkaya Uzan G; Paketçi C; Günay Ç; Edem P; Özsoy Ö; Hız Kurul S; Yiş U
    Neuropediatrics; 2022 Oct; 53(5):321-329. PubMed ID: 35871521
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Children and young adults with spinal muscular atrophy treated with nusinersen.
    Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
    Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Bishop KM; Foster R; Liu Y; Ramirez-Schrempp D; Schneider E; Bennett CF; Wong J; Farwell W
    Lancet Child Adolesc Health; 2021 Jul; 5(7):491-500. PubMed ID: 34089650
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
    Darras BT; Farrar MA; Mercuri E; Finkel RS; Foster R; Hughes SG; Bhan I; Farwell W; Gheuens S
    CNS Drugs; 2019 Sep; 33(9):919-932. PubMed ID: 31420846
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Respiratory care in spinal muscular atrophy in the new therapeutic era].
    Palomino MA; Castiglioni C
    Rev Chil Pediatr; 2018 Dec; 89(6):685-693. PubMed ID: 30725056
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Nusinersen by subcutaneous intrathecal catheter for symptomatic spinal muscular atrophy patients with complex spine anatomy.
    Carson VJ; Young M; Brigatti KW; Robinson DL; Reed RM; Sohn J; Petrillo M; Farwell W; Miller F; Strauss KA
    Muscle Nerve; 2022 Jan; 65(1):51-59. PubMed ID: 34606118
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treating adults with spinal muscular atrophy with nusinersen.
    Farrar MA; Kiernan MC
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1139. PubMed ID: 32917825
    [No Abstract]   [Full Text] [Related]  

  • 73. Long-term benefits of nusinersen in a child affected by cystic fibrosis and spinal muscular atrophy type 1.
    Bruno G; Donnarumma B; Inverardi A; Buonpensiero P; Sepe A; Tosco A; Raia V; Varone A
    Pediatr Pulmonol; 2021 Jun; 56(6):1806-1808. PubMed ID: 33684256
    [No Abstract]   [Full Text] [Related]  

  • 74. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
    Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
    J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
    [No Abstract]   [Full Text] [Related]  

  • 75. Skip constructs in spinal muscular atrophy: outcomes of a novel approach for posterior spinal instrumentation and fusion.
    Konigsberg MW; Matsumoto H; Ball JR; Roye BD; Vitale MG
    Spine Deform; 2020 Oct; 8(5):1093-1097. PubMed ID: 32253736
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
    Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
    J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen.
    Sansone VA; Coratti G; Pera MC; Pane M; Messina S; Salmin F; Albamonte E; De Sanctis R; Sframeli M; Di Bella V; Morando S; d'Amico A; Frongia AL; Antonaci L; Pirola A; Pedemonte M; Bertini E; Bruno C; Mercuri E;
    Eur J Neurol; 2021 Feb; 28(2):602-608. PubMed ID: 33012052
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Anesthetic management of pediatric patients undergoing intrathecal nusinersen administration for treatment of spinal muscular atrophy: A single-center experience.
    Brollier LD; Matuszczak M; Marri T; Carbajal JG; Moorman AT; Sorial EM; Jain R
    Paediatr Anaesth; 2021 Feb; 31(2):160-166. PubMed ID: 32623818
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Two Years of Improved Neurological Function With Nusinersen in a 48-Year-Old Patient With Spinal Muscular Atrophy Type 3.
    Shah JS; Rubin DI; Dimberg EL; Owens CR; Gicalone AR; De Oliveira G; Oskarsson BE
    Neurologist; 2020 Sep; 25(5):141-143. PubMed ID: 32925486
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ultrasound-guided nusinersen administration for spinal muscular atrophy patients with severe scoliosis: an observational study.
    Zhang J; Cui X; Chen S; Dai Y; Huang Y; Zhang S
    Orphanet J Rare Dis; 2021 Jun; 16(1):274. PubMed ID: 34120632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.